AMW GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AMW GmbH - overview
Established
2008
Location
Warngau, -, Germany
Primary Industry
Pharmaceuticals
About
AMW GmbH is a German pharmaceutical company specializing in innovative drug delivery systems. The firm focuses on biodegradable solutions that enhance patient adherence to therapy through controlled medication release. Founded in 2008, AMW GmbH operates in the pharmaceutical sector, developing specialized drug delivery systems. The company has completed 7 deals, with its most recent funding round completed on April 1, 2023, amounting to EUR 25.
00 mn, led by the European Investment Bank. The current CEO is Philipp Karbach. AMW GmbH offers innovative pharmaceutical products, mainly Goserelin and Leuprorelin, which are implantable drug delivery systems specifically designed for hormone-sensitive tumors. By employing biodegradable materials, these systems facilitate controlled medication release and aim to improve patient therapy adherence.
AMW distributes its products through various pharmaceutical and biotech partners globally, covering regions such as Europe, North America, and Asia. In the most recent financial year of 2021, AMW GmbH reported a revenue of EUR 16,561,912, with an EBITDA of EUR 6,079,099. 4 in 2023. The company primarily generates revenue through B2B partnerships with pharmaceutical firms that distribute its drug delivery systems under structured supply agreements.
AMW GmbH aims to expand its product portfolio by developing additional drug delivery systems slated for launch in the coming years. The company is also targeting expansion into new geographic markets in Asia and North America by 2025. Recent funding raised in April 2023, amounting to EUR 16. 5 mn, will support these initiatives, facilitating further product development and market entry efforts.
Current Investors
YF Capital, Shenzhen Hybio Engineering, KfW Banking Group
Primary Industry
Pharmaceuticals
Sub Industries
Biotechnology, Oncology/Cancer Treatment, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.amw-pharmaceuticals.com
Verticals
HealthTech, Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
AMW GmbH - timeline of key events
AMW GmbH - financials
| Fiscal Year Ended | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | 1,000,000 | 8,200,000 | 12,100,000 | 18,300,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | 720.0% | 47.6% | 51.2% | - | - | - |
| EBITDA (USD) | - | - | - | - | - | - | - | (2,179,515.2) | (251,739.3) | 58,129.1 | 2,624,955.9 | - | - | - |
| Operating Income (USD) | - | - | - | - | - | - | - | (2,659,928.9) | (834,074.5) | (569,822.1) | (4,300,587.2) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | (266.0%) | (10.2%) | (4.7%) | (23.5%) | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | (218.0%) | (3.1%) | 0.5% | 14.3% | - | - | - |
| NET Income (USD) | (3,168,598.3) | (3,644,751.7) | (2,606,572.3) | (2,222,089.2) | (2,799,238.1) | 144,813.8 | (2,229,110) | (3,123,059.9) | (3,021,695) | (1,673,017.9) | (4,633,329.2) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | (312.3%) | (36.8%) | (13.8%) | (25.3%) | - | - | - |
AMW GmbH - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.